The interim data provides clinical proof of concept for tagmokitug in ESCC, with response rates that compare favorably to standard-of-care benchmarks. Monitor for further data maturation and enrollment expansion in ESCC cohorts, as well as any regulatory interactions or partnership developments.
Price Chart
Executive Summary
Coherus Oncology announced interim clinical data from the TREGCHECK program for tagmokitug, an investigational CCR8 antibody, in combination with toripalimab. The data showed a 75% confirmed overall response rate (cORR) in evaluable first-line ESCC patients irrespective of PD-L1 status, and a 100% cORR in PD-L1 positive patients, with a manageable safety profile. The company plans to expand enrollment in ESCC cohorts based on these interim findings.
Key Facts
- In evaluable front-line ESCC patients, tagmokitug + toripalimab + chemo demonstrated a cORR of 75% irrespective of PD-L1 status and 100% in PD-L1 positive patients as of October 14, 2026.
- Post-data-cutoff, two additional partial responses increased the cORR to 89% of the evaluable patient dataset irrespective of PD-L1 status.
- In second-line ESCC at the 700 mg dose, median progression-free survival was 5.5 months vs a US standard-of-care benchmark of ~3.4 months.
- Tagmokitug demonstrated a manageable safety profile across over 120 patients in combination with toripalimab, with no new safety signals and no Grade 5 treatment-related adverse events.
- The company plans to expand enrollment in first-line and second-line ESCC cohorts based on the interim data.
Financial Impact
No financial figures were disclosed in the filing. The data supports continued clinical development of tagmokitug, a pipeline asset with no approved status or stated revenue.
Risk Factors
- Tagmokitug is investigational and has not been approved by the FDA or any regulatory authority; safety and efficacy are not established.
- Interim data are based on small patient numbers (8-9 evaluable in 1L ESCC, 6 evaluable in 2L ESCC at 700 mg) and may not be predictive of final results.
- The company's market cap is $165M, and it relies on its ability to raise funds to support development, as noted in the forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-119912 |
| Document: chrs-ex99d1.htm | 0001104659-26-119912 |
| Document: 0001104659-26-119912-index-headers.html | 0001104659-26-119912 |
| Document: 0001104659-26-119912-index.html | 0001104659-26-119912 |
| Document: 0001104659-26-119912.txt | 0001104659-26-119912 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $0.8984 | awaiting T+60 | awaiting T+60 | $0.8300 (−7.61%) |
Oct 14, 2026 18d ago | Press Release | $1.07 | awaiting T+60 | awaiting T+60 | $0.8300 (−22.43%) |
Aug 17, 2026 10w ago | Press Release | $1.34 | awaiting T+60 | awaiting T+60 | $0.8300 (−38.06%) |
Jul 22, 2026 14w ago | Press Release | $1.43 $1.07 | ▼ −25.17% | ▼ −28.44% | $0.8300 (−41.96%) |
Jun 15, 2026 19w ago | 8-K | $1.38 $1.34 | ▼ −2.90% | ▼ −3.90% | $0.8300 (−39.86%) |
Jun 12, 2026 20w ago | Institutional Cluster | $1.40 $1.37 | ▲ +2.14% | ▲ +5.41% | $0.8300 (+40.71%) |
May 28, 2026 22w ago | DEFA14A | $1.65 $1.42 | ▼ −13.94% | ▼ −15.67% | $0.8300 (−49.70%) |
May 11, 2026 24w ago | Press Release | $1.71 $1.27 | ▼ −26.02% | ▼ −30.41% | $0.8300 (−51.46%) |
May 5, 2026 25w ago | DEFA14A | $1.75 $1.41 | ▼ −19.43% | ▼ −21.49% | $0.8300 (−52.57%) |
May 4, 2026 25w ago | Press Release | $1.73 $1.41 | ▼ −18.50% | ▼ −20.35% | $0.8300 (−52.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers